Mehta, Nikita and Keung, Marco Ho Ting and Pineda, Eunice and Lynn, Elliott and Fetene, Dagnachew and Lee, Alvin and Hougardy, Nicolas and Heinrichs, Amelie and Chan, Hiu Tat Mark and Arbyn, Marc and Saville, Marion and Hawkes, David (2024) Clinical validation of the Roche cobas HPV test on the Roche cobas 5800 system for the purpose of cervical screening. Microbiology Spectrum, 12 (10). ISSN 2165-0497, DOI https://doi.org/10.1128/spectrum.01493-24.
Full text not available from this repository.Abstract
This study assessed the relative clinical sensitivity and specificity, as well as reproducibility, for high-risk HPV types of the Roche cobas HPV test when processed using the Roche cobas 5800 system. The results from this study demonstrate that the cobas HPV test using the cobas 5800 system fulfils the Meijer criteria for use in population-based cervical screening. This clinical validation study also examines the clinical sensitivity and specificity based on partial genotyping, with separate detection of HPV16 and HPV18, compared with the Roche cobas 4800 HPV test, a second-generation standard comparator assay. The cobas HPV test has a relative clinical sensitivity of 1.000, when compared with the cobas 4800 HPV test to detect histologically confirmed CIN2+ lesions in woman aged 30 years or older, with a relative clinical specificity of 0.995. The general intra- and inter-laboratory agreement for the cobas HPV test on the cobas 5800 system for finding a HPV positive result were 99.1% and 99.6%, respectively.IMPORTANCEThis study demonstrates, for the first time, the clinical performance of the Roche cobas HPV test when processed using the new cobas 5800 system cobas (5800)]. This study shows that the cobas (5800) demonstrates relative clinical sensitivity and specificity, when compared with a standard comparator HPV test, which meets the international HPV test validation requirements. Intra- and inter-laboratory reproducibility also fulfills these criteria. The current study demonstrates that the cobas (5800) can be used for primary HPV-based cervical screening on cervical specimens. This study demonstrates, for the first time, the clinical performance of the Roche cobas HPV test when processed using the new cobas 5800 system cobas (5800)]. This study shows that the cobas (5800) demonstrates relative clinical sensitivity and specificity, when compared with a standard comparator HPV test, which meets the international HPV test validation requirements. Intra- and inter-laboratory reproducibility also fulfills these criteria. The current study demonstrates that the cobas (5800) can be used for primary HPV-based cervical screening on cervical specimens.
| Item Type: | Article |
|---|---|
| Funders: | Australian Center, Roche Molecular Systems, European Commission, European Society of Gynecological Oncology, VALGENT, World Health Organization, Horizon 2020 Framework Program for Research and Innovation of the European Commission [Grant no. 847845], National Health and Medical Research Council-funded Center for Research Excellence in Cervical Cancer Control [Grant no. APP1135172] |
| Uncontrolled Keywords: | HPV; Clinical validation; Diagnostic; Cervical screening; Cervical intraepithelial neoplasia |
| Subjects: | R Medicine > RB Pathology R Medicine > RG Gynecology and obstetrics |
| Divisions: | Faculty of Medicine > Obstetrics & Gynaecology Department Faculty of Medicine > Pathology Department |
| Depositing User: | Ms. Juhaida Abd Rahim |
| Date Deposited: | 22 Oct 2025 01:38 |
| Last Modified: | 22 Oct 2025 01:38 |
| URI: | http://eprints.um.edu.my/id/eprint/46494 |
Actions (login required)
 |
View Item |
